-
EAU 2025 | Exploring Non-invasive Diagnosis and Combination Therapy for Renal Cancer — Professor Xiongjun Ye’s Team Advances Clinical Practice
1. UroStream: MRI has rapidly developed, but challenges remain in accurately identifying renal tumors. What advancements has your team made in this area? Professor Xiongjun Ye: Currently, the diagnosis of…
-
SGBCC 2025丨Professor Cicero Urban: New Perspectives—Redefining the Patient Population for Axillary Surgery in Early Breast Cancer
Oncology frontier: The current applicability of axillary surgery (such as SLNB or ALND) in early-stage breast cancer is a subject of controversy. In your report at SGBCC, you mentioned that…
-
SGBCC 2025 | Professor Cuizhi Geng: Multiple Posters Presented, China’s Innovations Take the Global Stage
Oncology Frontier: Your hospital presented multiple posters at this year’s SGBCC. Could you share some of the most notable advances? How will these posters contribute to the global development of…
-
EAU 2025 | Optimizing Prostate Biopsy Approaches: Prof. Kan Gong’s Team’s Peri-lesion Biopsy RCT Study Awarded at EAU
At the 40th Annual European Association of Urology (EAU) Congress, precision biopsy strategies and technological innovation were core topics in the prostate cancer field. With a focus on addressing the limitations of traditional systematic biopsies and MRI-targeted biopsies, multiple studies concentrated on optimizing biopsy approaches to balance diagnostic efficacy and safety. “UroStream” invited Professors Kan…
-
Eva Blondeaux contribution to redefining risk in HR+/HER2− early breast cancer
We are pleased to highlight the contribution of Dr. Eva Blondeaux to the latest publication in the Journal of the National Cancer Institute (published February 5, 2025), titled:“Prognostic implications of…
-
Tracking Molecular Shifts in High-Risk Luminal Breast Cancer: Insights from the Penelope-B Trial
Published on February 10, 2025, in Cancer Cell, this international effort led by Carsten Denkert and colleagues investigates the dynamics of therapy-induced molecular heterogeneity in high-risk HR+/HER2− breast cancer, using…
-
Professor Aiwen Wu：Should a “Watch and Wait” Approach Be Considered Before Treating Low Rectal Cancer? | Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee
In the treatment of low rectal cancer, the “watch and wait” strategy has sparked a compelling debate between organ preservation and radical resection. With the advancement of neoadjuvant therapies, some patients achieve clinical complete response (cCR) following chemoradiotherapy, opening the door to non-operative management and the possibility of avoiding a permanent stoma. However, concerns over…
Connecting Medical Expertise through Media
